These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19242316)

  • 1. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
    Pan C; Lu H; Qi Z; Jiang S
    AIDS; 2009 Mar; 23(5):639-41. PubMed ID: 19242316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
    Pan C; Cai L; Lu H; Qi Z; Jiang S
    J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Qiu Z; Xiong S; He Y
    J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The improved efficacy of Sifuvirtide compared with enfuvirtide might be related to its selectivity for the rigid biomembrane, as determined through surface plasmon resonance.
    Cao P; Dou G; Cheng Y; Che J
    PLoS One; 2017; 12(2):e0171567. PubMed ID: 28207776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.
    Liu Z; Shan M; Li L; Lu L; Meng S; Chen C; He Y; Jiang S; Zhang L
    J Biol Chem; 2011 Feb; 286(5):3277-87. PubMed ID: 21098485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide.
    Covens K; Megens S; Dekeersmaeker N; Kabeya K; Balzarini J; De Wit S; Vandamme AM; Van Laethem K
    Antiviral Res; 2010 Jun; 86(3):253-60. PubMed ID: 20227441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
    Qi Q; Wang Q; Chen W; Du L; Dimitrov DS; Lu L; Jiang S
    Emerg Microbes Infect; 2017 Jun; 6(6):e59. PubMed ID: 28634358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.
    He Y
    Curr Pharm Des; 2013; 19(10):1800-9. PubMed ID: 23092277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
    Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
    Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor.
    Ashkenazi A; Wexler-Cohen Y; Shai Y
    Biochim Biophys Acta; 2011 Oct; 1808(10):2352-8. PubMed ID: 21762676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibitors of fusion: a new alternative in the treatment of HIV infection].
    Roca Villanueva B
    Med Clin (Barc); 2004 May; 122(17):659-60. PubMed ID: 15153345
    [No Abstract]   [Full Text] [Related]  

  • 17. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
    Cooper DA; Lange JM
    Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel fusion inhibitor against T-20-resistant HIV-1.
    Oishi S; Ito S; Nishikawa H; Tanaka M; Ohno H; Otaka A; Izumi K; Kodama E; Matsuoka M; Fujii N
    Adv Exp Med Biol; 2009; 611():389-91. PubMed ID: 19400237
    [No Abstract]   [Full Text] [Related]  

  • 19. Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains.
    Wang C; Shi W; Cai L; Lu L; Yu F; Wang Q; Jiang X; Xu X; Wang K; Xu L; Jiang S; Liu K
    J Antimicrob Chemother; 2014 Jun; 69(6):1537-45. PubMed ID: 24500189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.
    Cai L; Pan C; Xu L; Shui Y; Liu K; Jiang S
    FASEB J; 2012 Mar; 26(3):1018-26. PubMed ID: 22085645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.